



## Development of Novel Tumor-Targeting Nanoparticles, 2nd Edition

Guest Editors:

**Dr. Andrea Lancia**

Radiation Oncology Unit,  
Department of Medical Sciences  
and Infectious Disease,  
Fondazione IRCCS, Policlinico  
San Matteo, Pavia, Italy

**Dr. Alexander Zaboronok**

Department of Neurosurgery,  
University of Tsukuba, Tsukuba,  
Tennodai, Japan

**Dr. Bryan Mathis**

International Medical Center,  
University of Tsukuba Affiliated  
Hospital, Tsukuba 305-8576,  
Japan

Deadline for manuscript  
submissions:

**30 October 2024**

### Message from the Guest Editors

Dear Colleagues,

Based on the success of Volume I of the Special Issue "Development of Novel Tumor-Targeting Nanoparticles" <https://www.mdpi.com/journal/pharmaceutics/special-issue/artic/00000> we are now launching Volume II. Below is the instruction for it.

Cancer remains one of the most pressing problems of humankind, killing about 10 million people in 2020, according to statistics from the World Health Organization. Based on numerous published reports, nanoparticles (including liposomes, micelles, etc.) are capable of delivering much larger volumes of active components that stay sequestered in tumor cells for the time required for treatment, and with sufficient active targeting, nanoparticles would have enormous therapeutic potential. Therefore, innovating new tumor-targeting nanoparticles that can change the history of cancer treatment and save the lives of millions of people should be a priority. Therefore, we invite researchers participate in such groundbreaking work to participate in a Special Issue of the journal by submitting their articles for publication in Pharmaceutics.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Patrick J. Sinko**

Department of Pharmaceutics,  
Ernest Mario School of  
Pharmacy, Rutgers University,  
Piscataway, NJ 08854, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceutics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma